These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31399302)

  • 1. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
    Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
    Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
    Chiang CL; So TH; Lam TC; Choi HCW
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
    Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
    Barqawi YK; Borrego ME; Roberts MH; Abraham I
    J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    Parikh NR; Chang EM; Nickols NG; Rettig MB; Raldow AC; Steinberg ML; Koontz BF; Vapiwala N; Deville C; Feng FY; Spratt DE; Reiter RE; Phillips R; Ost P; Tran PT; Kishan AU
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):917-926. PubMed ID: 32544574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
    Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
    PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
    Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Sung WWY; Choi HCW; Luk PHY; So TH
    Front Oncol; 2021; 11():627083. PubMed ID: 33718198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen NJ; Lawrentschuk N; Konety B; Azad AA; Corcoran NM; Bolton DM; Murphy DG
    Eur Urol Oncol; 2024 Aug; 7(4):870-876. PubMed ID: 38057191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer.
    Handorf EA; Beck JR; Correa A; Ramamurthy C; Geynisman DM
    Med Decis Making; 2023; 43(7-8):949-960. PubMed ID: 37811793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
    Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
    J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
    J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
    Liu M; Qu S; Liu Y; Yao X; Jiang W
    J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
    [No Abstract]   [Full Text] [Related]  

  • 20. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P; Manka L
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.